J
José Bines
Researcher at Rio de Janeiro Federal Institute of Education, Science and Technology
Publications - 84
Citations - 3173
José Bines is an academic researcher from Rio de Janeiro Federal Institute of Education, Science and Technology. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 20, co-authored 64 publications receiving 2487 citations. Previous affiliations of José Bines include Memorial Sloan Kettering Cancer Center & University of Southern California.
Papers
More filters
Journal ArticleDOI
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz,Marion Procter,Evandro de Azambuja,Dimitrios Zardavas,Mark C. Benyunes,Giuseppe Viale,Thomas M. Suter,Amal Arahmani,Nathalie Rouchet,Emma Clark,Adam Knott,István Láng,Christelle Levy,Denise A. Yardley,José Bines,Richard D. Gelber,Martine Piccart,José Baselga +17 more
TL;DR: Pertuzumab significantly improved the rates of invasive‐disease–free survival among patients with HER2‐positive, operable breast cancer when it was added to adjuvant chemotherapy and chemotherapy.
Journal ArticleDOI
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Stephen Chia,William J. Gradishar,Louis Mauriac,José Bines,Frédéric Amant,Miriam Hatsue Honda Federico,Luis Fein,Gilles Romieu,Aman U. Buzdar,John F.R. Robertson,Adam Brufsky,Kurt Possinger,Pamela Rennie,Francisco Sapunar,Elizabeth S. Lowe,Martine Piccart +15 more
TL;DR: Fulvestrant LD and exemestane are equally active and well-tolerated in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteroidal AI.
Journal ArticleDOI
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo,Henry L. Gomez,Zeba Aziz,Zanete Zvirbule,José Bines,M. Arbushites,Stephanie F. Guerrera,Maria Koehler,Cristina Oliva,S. Stein,L. S. Williams,Judy Dering,Richard S. Finn,Michael F. Press +13 more
TL;DR: First-line therapy with paclitaxel-lapatinib significantly improved clinical outcomes in HER-2-positive patients, and Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic breast cancer patients.
Journal ArticleDOI
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Martine Piccart,Marion Procter,Debora Fumagalli,Evandro de Azambuja,Emma Clark,Michael S. Ewer,Eleonora Restuccia,Guy Jerusalem,Susan Dent,Linda Reaby,Hervé Bonnefoi,Ian E. Krop,Tsang Wu Liu,Tadeusz Pienkowski,Masakazu Toi,Nicholas Wilcken,Nicholas Wilcken,Michael Andersson,Young-Hyuck Im,Ling Ming Tseng,Hans-Joachim Lueck,Marco Colleoni,Estefania Monturus,Mihaela Sicoe,Sebastien Guillaume,José Bines,Richard D. Gelber,Giuseppe Viale,Christoph Thomssen,Investigators +29 more
TL;DR: PURPOSEAPHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumaab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 081).
Journal ArticleDOI
Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation.
Alexandru Eniu,Robert W. Carlson,Nagi S. El Saghir,José Bines,Nuran Bese,Daniel A. Vorobiof,Riccardo Masetti,Benjamin O. Anderson +7 more
TL;DR: An international panel of experts addressed the implementation of treatment guidelines and developed process checklists for breast surgery, radiation treatment, and systemic therapy, and the use of process metrics can facilitate the development of multidisciplinary, integrated, fiscally responsible, continuously improving, and flexible approaches to the global enhancement of breast cancer treatment.